PT - JOURNAL ARTICLE AU - Experton, Bettina AU - Tetteh, Hassan A. AU - Lurie, Nicole AU - Walker, Peter AU - Carroll, Colin J. AU - Elena, Adrien AU - Hein, Christopher S. AU - Schwendiman, Blake AU - Burrow, Christopher R. TI - A Multi-Factor Risk Model for Severe Covid-19 for Vaccine Prioritization and Monitoring Based on a 15 Million Medicare Cohort AID - 10.1101/2020.10.28.20219816 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.28.20219816 4099 - http://medrxiv.org/content/early/2020/11/03/2020.10.28.20219816.short 4100 - http://medrxiv.org/content/early/2020/11/03/2020.10.28.20219816.full AB - Background Public Health interventions to slow the spread of the Covid-19 pandemic focus on protecting individuals at risk for severe disease. Risk categorization is essential to effective pandemic response. However, existing risk models for severe Covid-19 lack needed integration of both socio-demographic and clinical risk factors, and geographic characteristics.Methods We present an integrated multi-factor risk model for severe Covid-19 using de-identified Medicare claims from which we extracted demographic and clinical data for a cohort of 15 million Medicare beneficiaries with 770,000 Covid-19 cases, and socio-economic data at the county and zip code level from the CDC Social Vulnerability Index. The model and associated digital maps were developed as part of Project Salus of the Department of Defense Joint Artificial Intelligence Center, for use by the National Guard and other military personnel in their support mission to hospitals and local jurisdictions impacted by the pandemic.Results The model affirms ethnicity (Black: OR 1.64; 95% CI 1.61–1.68, American Indian: OR 2.21; 95% CI 2.01-2.42), age over 85 (OR 1.75, 95% CI 1.69-1.81), the socio-economic factor of residing in a zip code in the lowest quartile of income (OR 1.23; 95% CI 1.21-1.26), ESRD (OR 2.35; 95% CI 2.25-2.45) and chronic lung disease (OR 1.95; 95% CI 1.90-2.00) as leading risk factors for Covid-19 hospitalizations, but reveals low risk for COPD (OR 1.15; 95% CI 1.13−1.17) and minimal or no risk for diabetes (OR 1.03; CI 1.01-1.05), CHF (OR 1.10, 95% CI 1.08-1.12) or hypertension (OR 0.96; 95% CI 0.94-0.98), and demonstrates an association between prior herpes zoster immunization (OR 0.74; 95% CI 0.71-0.77), and to a lesser degree prior influenza and pneumococcal vaccines with less severe Covid-19.Conclusions This multi-factor risk model and derived digital maps can be applied for use by national and local health authorities to augment existing tools for pandemic response, including monitoring of post Covid-19 sequelae, prioritization of Covid-19 vaccine, and vaccine monitoring for both safety and efficacy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Johns Hopkins University Applied Physics Laboratory (JHU-APL) under a prime contract with the Department of Defense Joint Artificial Intelligence Center (JAIC) for Project Salus. Project Salus is a JAIC project in support of the National Guard and other military personnel to provide needed supplies and personnel to health care facilities impacted by the Covid-19 pandemic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was carried out under the supervision of the Department of Defense Joint Intelligence Center under a data use agreement with CMS.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Medicare claim data files used in this research is protected health information as defined by the Health Insurance Portability and Accountability Act (HIPAA). Access to these data sets require CMS approval. The 2018 CDC Social Vulnerability Index data can be downloaded from the CDC website. https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html